MNPR
A new bull on the block
Monopar Therapeutics just got a fresh wall of optimism slapped on it: coverage initiated with a Buy and a $145 price target. That’s not pocket change territory — it’s a pretty loud vote of confidence for a small biotech trying to turn one asset into a much bigger story.
Why the market might care
The pitch is centered on ALXN1840, Monopar’s Wilson disease candidate. The analyst points to significant neurological benefit and copper mobilization in Phase 3 data, plus an impressive number needed to treat of six. In biotech land, that’s the kind of thing that can make investors sit up a little straighter in their chairs.
The valuation math is doing a lot of the heavy lifting here:
- about $750 million in global peak sales
- an 80% probability of success
- cash runway stretching through 2027
That combo suggests the story isn’t just “hope and vibes.” It’s “hope, vibes, and enough cash to survive the waiting game.”
What to watch next
For investors, the next checkpoints are the usual biotech cliffhangers: regulatory progress, commercialization plans, and whether the data story keeps holding up when it gets stress-tested by real-world scrutiny. If ALXN1840 keeps winning believers, Monopar could stop being a sleepy microcap and start looking a lot more interesting.
Big picture: this is still a high-risk biotech bet, but the new coverage gives Monopar a very visible upside narrative — and in small-cap drug stocks, narrative can move the needle fast.